Immune modulation therapy: VAS will begin in 4Q02 a North American Phase III trial in about 1,500 patients. Previously reported data from a North American Phase

Vasogen Inc. (TSE:VAS; VSV), Toronto, Ontario
Product: Immune modulation therapy (formerly

Read the full 115 word article

How to gain access

Continue reading with a
two-week free trial.